Simultaneous Assessment of Cyclin D1 and Epidermal Growth Factor Receptor Gene Copy Number for Prognostic Factor in Oral Squamous Cell Carcinomas

Oral Science International

Volumn 6, Issue 1, 2009, Pages 8-20

  Takahashi, Ken Ichiro ^a   Uzawa, Narikazu ^a   Myo, Kunihiro ^a   Okada, Norihiko ^b   Amagasa, Teruo ^a  

^a Maxillofacial Surgery Department of Maxillofacial Reconstruction and Function Division of Maxillofacial and Neck Reconstruction   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

cyclin D1; EGFR; FISH; oral cancer

Indexed keywords

EID: 85009564893     PISSN: 13488643     EISSN: None     Source Type: Journal    
DOI: 10.11277/osi.6.8     Document Type: Article

References (51)

1. Vokes E. E., Weichselbaum R. R., Lippman S.M., and Hong W.K.: Head and neck cancer. N Engl J Med 328:184–194, 1993.
2. Parkin DM., Läärä E., and Muir CS.: Estimates of the worldwide frequency of 16 major cancers in 1980. Int J Cancer 41:184–197, 1988.
3. Boring CC., Squires TS., Tong T., and Montgomery S.: Cancer statistics, 1994. CA Cancer J Clin 44:7–26, 1994.
4. Califano J., van der Riet P., Westra W., Nawroz H., Clayman G., Piantadosi S., Corio R., Lee D., Greenberg B., Koch W., and Sidransky D.: Genetic progression model for head and neck cancer: implication for field cancerization. Cancer Res 56:2488–2492, 1996.
5. Meredith SD., Levine PA., Burns JA., Gaffey MJ., Boyd JC., Weiss LM., Erickson NL., and Williams ME.: Chromosome 11q13 amplification in head and neck squamous cell carcinoma: association with poor prognosis. Arch Otolaryngol Head Neck Surg 121 : 790–794, 1995.
6. Muller D., Millon R., Velten M., Bronner G., Jung G., Engelmann A., Flesch H., Eber M., Methlin G., and Abe-cassis J.: Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome. Eur J Cancer 33 : 2203–2210, 1997.
7. Schuuring E.: The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes. Gene 159 : 83–96, 1995.
8. Shinozaki H., Ozawa S., Ando N., Tsuruta H., Terada M., Ueda M., and Kitajima M.: Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res 2 : 1155–1161, 1996.
9. Nagasawa S., Onda M., Sasajima K., Makino H., Yamashita K., Takubo K., and Miyashita M.: Cyclin D1 overexpression as a prognostic factor in patients with esophageal carcinoma. J Surg Oncol 78 : 208–214, 2001.
10. Namazie A., Alavi S., Olopade OI., Pauletti G., Aghamohammadi N., Aghamohammadi M., Gornbein JA., Calcaterra TC, Slamon DJ., Wang MB., and Srivatsan ES.: Cyclin D1 amplification and P16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 112 : 472–481, 2002.
11. Kyomoto R., Kumazawa H., Toda Y., Sakaida N., Okamura A., Iwanaga M., Shintaku M., Yamashita T., Hiai H., and Fukumoto M.: Cyclin D1 gene amplification is a more potent prognostic factor than its protein overexpresion in human head and neck squamous cell carcinoma. Int J Cancer 74 : 576–581, 1997.
12. Miyamoto R., Uzawa N., Nagaoka S., Nakakuki K., Hirata Y., and Amagasa T.: Potential marker of oral squamous cell carcinoma aggressiveness detected by fluorescence in situ hybridization in fine-needle aspiration biopsies. Cancer 95 : 2152–2159, 2000.
13. Miyamoto R., Uzawa N., Nagaoka S., Hirata Y., and Amagasa T.: Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol 39 : 610–618, 2003.
14. Myo K., Uzawa N., Miyamoto R., Sonoda I., Yuki Y., and Amagasa T.: Cyclin D1 gene numerical aberration is a predictive marker for occult cervical lymph node metastasis in TNM stage I and II squamous cell carcinoma of the oral cavity. Cancer 104 : 2709–2716, 2005.
15. Bellacosa A., Almadori G., Cavallo S., Cadoni G., Galli J., Ferrandina G., Scambia G., and Neri G.: Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 2 : 175–180, 1996.
16. Bova RJ., Quinn DI., Nankervis JS., Cole IE., Sheridan BF., Jensen MJ., Morgan GJ., Hughes CJ., and Sutherland RL.: Cyclin D1 and p 16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 5 : 2810–2819, 1999.
17. Grandis JR., and Tweardy DJ.: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 : 3579–3584, 2003.
18. Ang KK., Berkey BA., Tu X., Zhang HZ., Katz R., Hammond EH., Fu KK., and Milas L.: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 : 7350–7356, 2002.
19. Cohen EE., Rosen F., Stadler WM., Recant W., Stenson K., Huo D., and Vokes EE.: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 : 1980–1987, 2003.
20. Baselga J., Trigo JM., Bourhis J., Tortochaux J., Cortés-Funes H., Hitt R., Gascón P., Amellal N., Harstrick A., and Eckardt A.: Phase II multicenter study of the antiepider-mal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 : 5568–5577, 2005.
21. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E. K., and Ang K.K.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 : 567–578, 2006.
22. Hirsch F.R., Varella-Garcia M., Bunn P.A. Jr., Di Maria M.V., Veve R., Bremmes R.M., Barón A.E., Zeng C., and Franklin W.A.: Epidermal Growth Factor Receptor in Non—Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis J Clin Oncol 20 : 3798–3807, 2003.
23. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A. C., Gumerlock P., Bunn P.A. Jr., Franklin W.A., Crowley J., and Gandara D.R.: Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group study. J Clin Oncol 23 : 6838–6845, 2005.
24. Cappuzzo F., Hirsch F. R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domeni-chini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn P.A. Jr., and Varella-Garcia M.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655, 2005.
25. Kalish LH., Kwong RA., Cole IE., Gallagher RM., Sutherland RL., and Musgrove EA.: Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 10:7764–7774, 2004.
26. Sobin LH., Wittekind C., editors.: International Union Against Cancer. TNM classification of malignant tumors. 5th ed. New York John Wiley & Sons 1997.
27. World Health Organization. International histological classification of tumors 2nd ed. Berlin, Germany : Springer-Verlag, 1999.
28. Sunpaweravong P., Sunpaweravong S., Puttawibul P., Mitarnun W., Zeng C., Barón AE., Franklin W., Said S., and Varella-Garcia M.: Epidermal growth factor receptor and cyclin D1 are independently amplified and overex-pressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131:111–119, 2005.
29. Uzawa N., Sonoda I., Myo K., Takahashi K., Miyamoto R., and Amagasa T. : Fluorescence in situ hybridization for detecting genomic alterations of cyclin D1 and p 16 in oral squamous cell carcinomas. Cancer 110:2230–2239, 2007.
30. Skacel M., Ormsby AH., Pettay JD., Tsiftsakis EK., Liou LS., Klein EA., Levin HS., Zippe CD., and Tubbs RR.: Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: A differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Human pathol 32:1392–1397, 2001.
31. Renan MJ.: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139–146, 1993.
32. Yamamoto T., Kamata N., Kawano H., Shimizu S., Kuroki T., Toyoshima K., Rikimaru K., Nomura N., Ishizaki R., Pastan I., Gamou S., and Shimizu N.: High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res 46:414–416, 1986.
33. Kamata N., Chida K., Rikimaru K., Horikoshi M., Enomoto S., and Kuroki T. : Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture. Cancer Res 46:1648–1653, 1986.
34. Morrison LE., Jacobson KK., Friedman M., Schroeder JW., and Coon JS.: Aberrant EGFR and chromosome 7 associate with outcome in laryngeal cancer. Laryngoscope 115: 1212–1218, 2005.
35. Mrhalova M., Plzak J., Betka J., and Kodet R.: Epidermal growth factor receptor: Its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 52:338–343, 2004.
36. Chung CH., Ely K., McGavran L., Varella-Garcia M., Parker J., Parker N., Jarrett C., Carter J., Murphy BA., Netterville J., Burkey BB., Sinard R., Cmelak A., Levy S., Yarbrough WG., Slebos RJ., and Hirsch FR.: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170–4176, 2006.
37. Smid EJ., Stoter TR., Bloemena E., Lafleur MV., Leemans CR., van der Waal I., Slotman BJ., and Langendijk JA.: The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 65:1323–1329, 2006.
38. Gebhart E., Ries J., Wiltfang J., Liehr T., and Efferth T. : Genomic gain of the epidermal growth factor receptor harboring band 7p 12 is part of a complex pattern of genomic imbalances in oral squamous cell carcinomas. Arch Med Res 35:385–394, 2004.
39. Götte K., Schäfer C., Riedel F., Arens N., and Hörmann K.: Intratumoral genomic heterogeneity in primary head and neck cancer and corresponding metastases detected by dual-FISH. Oncol Rep 11:17–23, 2004.
40. Alcaraz A., Takahashi S., Brown JA., Herath JF., Bergstralh EJ., Larson-Keller JJ., Lieber MM., and Jenkins RB.: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998–4002, 1994.
41. Veltman JA., Bot FJ., Huynen FC., Ramaekers FC., Manni JJ., and Hopman AH.: Chromosome Instability as an Indicator of Malignant Progression in Laryngeal Mucosa. J Clin Oncol 18:1644–1651, 2000.
42. Reshmi SC., and Gollin SM.: Chromosomal instability in oral cancer cells. J Dent Res 84:107–117, 2005.
43. Shuster MI., Han L., Le Beau MM., Davis E., Sawicki M., Lese CM., Park NH., Colicelli J., and Gollin SM. : A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model for 11q13 amplification. Genes Chromosomes Cancer 28:153–163, 2000.
44. Singer MJ., Mesner LD., Friedman CL., Trask BJ., and Hamlin JL.: Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci USA 97:7921–7926, 2000.
45. Scaltriti M., and Baselga J.: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12:5268–5272, 2006.
46. Ruff-Jamison S., Zhong Z., and Wen Z., Chen K., Darnell JE Jr., Cohen S.: Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J Biol Chem 269:21933–21935, 1994.
47. Zhong Z., Wen Z., and Darnell J.E. Jr.: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95–98, 1994.
48. Darnell J.E. Jr.: STATs and gene regulation. Science 277: 1630–1635, 1997.
49. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot RP., and Jove R.: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545–2552, 1998.
50. Shao H., Cheng HY., Cook RG., and Tweardy DJ.: Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63:3923–3930, 2003.
51. Sriuranpong V., Park JI., Amornphimoltham P., Patel V., Nelkin BD., and Gutkind JS.: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp 130 cytokine system. Cancer Res 63:2948–2956, 2003.